Nyxoah SA（NYXH）股票分析

AI 分析 of Nyxoah SA (NYXH)

持有

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.

估值指標

Nyxoah SA（NYXH）目前預期本益比為 0.00，5 年平均預期本益比為 -4.19。

預期本益比

高估

5 年均值 P/E

-4.19

目前P/E

0.00

高估

-0.85

低估

-7.52

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-3.12

目前EV/EBITDA

-0.42

高估

-0.25

低估

-5.99

預期股價營收比

合理

5 年均值 P/S

23.23

目前P/S

1.26

高估

45.85

低估

0.61

Alphio AI 對 NYXH 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%NYXH

$9.24

情境價格

基

基準

基準 · 50%NYXH

$7.86

情境價格

悲

悲觀

悲觀 · 25%NYXH

$7.48

情境價格

持有 NYXH 的大戶

P

Pentwater Capital Management LP

+ 持有NYXH

-3.88%

3個月報酬率

NYXH 常見問題 —— 由 Alphio AI 解答

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.